Preclinical evaluation of the fluorinated 2-nitroimidazole n-(2-hydroxy- 3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia

Cancer Research

Volumn 57, Issue 15, 1997, Pages 3314-3318

  Aboagye, Eric O ^a,f   Maxwell, Ross J ^b   Kelson, Andrew B ^c   Tracy, Michael ^c   Lewis, Alexander D ^a   Graham, Martin A ^a   Horsman, Michael R ^d   Griffiths, John R ^e   Workman, Paul ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c SRI INTERNATIONAL   (United States)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DATA ANALYSIS; DNA DAMAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; CARBON DIOXIDE; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; FEMALE; FLUORINE; HYDRALAZINE; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; OXYGEN; REPRODUCIBILITY OF RESULTS;

EID: 0030744656     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res., 49: 6449-6465, 1989.
2. Hall, E. J. The oxygen effect and reoxygenation. In: E. J. Hall (ed.), Radiobiology for the Radiologist, pp. 137-160. Philadelphia: Lippincott Co., 1988.
3. Coleman, C. N. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J. Natl. Cancer Inst., 80: 310-317, 1988.
4. Powers, W. E., and Tolmach, L. J. A multi-component X-ray survival curve for mouse lymphosarcoma cells irradiated in vivo. Nature (Lond.), 197: 710-711, 1963.
5. Workman, P. New drugs against hypoxic cells. Cancer Topics, 4: 54-55, 1983.
6. Chapman, J. D. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother. Oncol., 20: S13-S19, 1991.
7. Stone, H. B., Brown, J. M., Phillips, T. L., and Sutherlands, R. M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Radiat. Res., 136: 422-434, 1993.
8. 19F magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol. Biol. Phys., 16: 925-929, 1988.
9. Walton, M. I., and Workman, P. Nitroimidazole bioreductive metabolism: quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem. Pharmacol., 36: 887-896, 1987.
10. 2 at the cellular level. Br. J. Cancer, 54: 453-457, 1986.
11. Chapman, J. D., Baer, K., and Lee, J. Characteristics of the metabolism-induced binding if misonidazole to hypoxic mammalian cells. Cancer Res., 43: 1523-1528, 1983.
12. Aboagye, E. O., Lewis, A. D., Johnson, A., Workman, P., Tracy, M., and Huxham, I. M. The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semi-quantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Br. J. Cancer, 72: 312-318, 1995.
13. Chapman, J. D. The detection and measurement of hypoxic cells in solid tumors. Cancer (Phila.), 54: 2441-2449, 1984.
14. Workman, P., Maxwell, R. J., and Griffiths, J. R. Non-invasive MRS in new anticancer drug development. NMR Biomed., 5: 270-272, 1992.
15. Workman, P., and Brown, J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother. Pharmacol., 6: 39-49, 1981.
16. 19F magnetic resonance spectroscopy. Int. J. Radiat. Biol., 58: 1025-1034, 1990.
17. 19F magnetic resonance method for measuring oxygen deficiency in tumors. Magn. Reson. Med., 22: 451-466, 1991.
18. 19F magnetic resonance spectroscopy and immunohistochemistry. Radiat. Res., 129: 71-78, 1992.
19. Aboagye, E. O., Lewis, A. D., Graham, M. A., Tracy, M., Kelson, A. B., Ryan, K. J., and Workman, P. The pharmacokinetics, bioavailability, and biodistribution of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anti-Cancer Drug Design, 11: 231-242, 1996.
20. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer, 72: 869-874, 1995.
21. Evans, S. M., Joiner, B., Jenkins, W. T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br. J. Cancer, 72: 875-882, 1995.
22. Aboagye, E. O., Graham, M. A., Lewis, A. D., Workman, P., Kelson, A. B., and Tracy, M. Development and validation of a solid phase extraction and high performance liquid Chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma. J. Chromatogr. Biomed. Appl., 672: 125-132, 1995.
23. 1. A scheme for analysis of in vivo metabolites. J. Magn. Reson., 55: 357-371, 1983.